TNF-α inhibitors

被引:39
作者
Jackson, J. Mark [1 ]
机构
[1] Univ Louisville, Div Dermatol, Louisville, KY 40202 USA
关键词
adalimumab; biologic agents; etanercept; infliximab; monoclonal antibody (MAB); psoriasis; psoriatic arthritis; TNF-alpha;
D O I
10.1111/j.1529-8019.2007.00138.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Tumor necrosis-alpha (TNF-alpha) has been implicated in many forms of inflammation and is an end-stage product of the inflammatory cytokine cascade. It is an inducer of inflammation and is involved in many cutaneous and systemic inflammatory diseases. The development of agents that block the effects of TNF-alpha has aided in the treatment of many of these diseases. This article will briefly discuss the production, structure, and administration of the TNF-alpha inhibitors. There will be a focus on the mechanism of action of each of the TNF-alpha inhibitors as well as their benefit in their FDA approved and non FDA approved dermatologic conditions. The side effect profile and monitoring recommendations for these agents will also be discussed.
引用
收藏
页码:251 / 264
页数:14
相关论文
共 84 条
[1]  
Abbott Laboratories, HUM PRESCR INF
[2]   Severe hidradenitis Suppurativa treated with infliximab infusion [J].
Adams, DR ;
Gordon, KB ;
Devenyi, AG ;
Ioffreda, MD .
ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1540-1542
[3]   Off-label dermatologic uses of anti-TNF-a therapies [J].
Alexis, Andrew F. ;
Strober, Bruce E. .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (06) :296-302
[4]   How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH [J].
Anker, SD ;
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) :123-130
[5]   Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].
Antoni, C ;
Krueger, GG ;
de Vlam, K ;
Birbara, C ;
Beutler, A ;
Guzzo, C ;
Zhou, B ;
Dooley, LT ;
Kavanaugh, A .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157
[6]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[7]   Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review [J].
Atzeni, F ;
Sarzi-Puttini, P ;
Doria, A ;
Iaccarino, L ;
Capsoni, F .
AUTOIMMUNITY REVIEWS, 2005, 4 (03) :144-152
[8]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[9]   Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides:: an open pilot study on 10 patients [J].
Bartolucci, P ;
Ramanoelina, J ;
Cohen, P ;
Mahr, A ;
Godmer, P ;
Le Hello, C ;
Guillevin, L .
RHEUMATOLOGY, 2002, 41 (10) :1126-1132
[10]  
Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635